KCT0001682招募中未知
A Randomized, Active-controlled, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of the Long-acting Antibody-fused Recombinant Human Growth Hormone (GX-H9) in Adult Growth Hormone Deficiency (AGHD)
Genexine0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •Each subject must meet all of the following criteria to be enrolled in this study:
- •1.Is a male or female aged =20 and 65 years with adult growth hormone deficiency (AGHD), either adult onset GHD due to hypothalamic pituitary disease or childhood onset GHD that is either idiopathic or due to hypothalamic pituitary disease or due to genetic causes.
- •2.Has documented confirmation (medical history) of growth hormone (GH) deficiency during adulthood by 1 or more GH stimulation tests, as follows:
- •?Insulin tolerance test (peak human growth hormone (hGH)=3.0 ng/mL)
- •?Arginine + growth-hormone-releasing hormone (peak hGH=4.0 ng/mL)
- •3.Has been treated with stable hormonal replacement therapies for deficiencies of other hypothalamo pituitary axes and must have been on an optimized and stable treatment regimen for at least 3 months before screening (free thyroxine [T4] level within normal range at screening). Temporary adjustment of glucocorticoid replacement therapy, as appropriate, is acceptable.
- •4.Has a screening insulin-like growth factor-1 (IGF-1) level of at least 1 standard deviation (SD) (IGF-1 SD score <1) below the mean IGF-1 level standardized for age and gender according to the central laboratory reference values.
- •5.Has a body mass index (BMI) of =18.0 and 35.0 kg/m2 (both male and female subjects).
- •6.Has a confirmed negative test result for anti-recombinant human growth hormone (anti-rhGH) antibodies at screening.
- •7.Must agree to use appropriate contraceptive methods (ie, condoms, cervical cap in conjunction with spermicide, sterilization, and intra uterine device) during the study and for 6 months after the last dose of study drug.
- •8.Female subjects must have a negative serum pregnancy test result at screening.
- •9.Must be willing and able to provide written informed consent before performing any study procedures.
排除标准
- •A subject meeting any of the following criteria will be excluded from the study:
- •1.Has evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months which has to be confirmed by computed tomography or magnetic resonance imaging scan (with contrast) within 3 months before screening. (Subjects with inactive remnant intracranial tumors are eligible).
- •2.Is currently receiving antitumor therapy and has a history of malignancy other than i) cranial tumor or leukemia causing growth hormone deficiency (GHD), or ii) fully treated basal cell carcinoma or evidence of active malignancy.
- •3.Has any clinically significant electrocardiogram (ECG) abnormality at screening.
- •4.Has evidence of intracranial hypertension at screening.
- •5.Has uncontrolled diabetes mellitus with diet and exercise, as determined based on glycated hemoglobin (HbA1c) levels =7.0% at screening.
- •6.Has impaired liver function defined as elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 × upper limit of normal (ULN).
- •7.Has impaired kidney function defined as increased serum creatinine levels greater than 1.5 × ULN.
- •8.Has had active acromegaly within 18 months before screening.
- •9.Has active carpal tunnel syndrome.
- •10.Has Prader-Willi syndrome.
- •11.Has had active Cushing syndrome within 12 months before screening.
- •12.Has any other major medical conditions, including eg, clinically manifested hypertension, tuberculosis, major surgery within the 3 months before screening, or significantly abnormal laboratory test results (eg, disturbed calcium homeostasis); or any other conditions (eg, acute infections) that may influence drug absorption, metabolism, or excretion, or that may interfere with any study variables in the judgment of the investigator.
- •13.Has been treated with systemic corticosteroids other than replacement therapy within 3 months before screening.
- •14.Is a female subject of childbearing potential who is pregnant, breastfeeding, or intends to become pregnant.
- •15.Has been treated with anabolic steroids other than gonadal steroid replacement therapy within 2 months before screening. Oral estrogen replacement and hormonal contraceptives are not allowed in female subjects. For replacement purposes, transdermal estrogens are permitted in female subjects.
- •16.Has a history of noncompliance with medications, uncooperativeness, or alcohol/drug abuse.
- •17.Has a positive result from serology examination for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- •18.Has a known or suspected hypersensitivity to recombinant growth hormone (rhGH).
- •19.Has donated blood or had any major blood loss greater than 500 mL within 90 days before screening.
- •20.Has a history of any medical or psychiatric condition that in the opinion of the investigator would pose a risk for participation in this study or interfere with the compliance needed for this study.
- •21.Has received an investigational drug or product or has participated in a drug study within 60 days before screening.
研究者
相似试验
进行中（未招募）
1 期
A clinical study in AGHD to assess safety, tolerability and efficacy of GX-H9Adult Growth Hormone Deficiency (AGHD)MedDRA version: 18.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-002698-13-HUGenexine, Inc45
进行中（未招募）
1 期
A clinical study in AGHD to assess safety, tolerability and efficacy of GX-H9EUCTR2014-002698-13-PLGenexine, Inc60
进行中（未招募）
1 期
A clinical study in AGHD to assess safety, tolerability and efficacy of GX-H9Adult Growth Hormone Deficiency (AGHD)MedDRA version: 18.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-002698-13-DEGenexine, Inc45
进行中（未招募）
1 期
A clinical study in AGHD to assess safety, tolerability and efficacy of GX-H9Adult Growth Hormone Deficiency (AGHD)MedDRA version: 17.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-002698-13-GRGenexine, Inc60
进行中（未招募）
1 期
A clinical study in AGHD to assess safety, tolerability and efficacy of GX-H9Adult Growth Hormone Deficiency (AGHD)MedDRA version: 17.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-002698-13-SEGenexine, Inc60